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Abstract
Background: To describe patients with inherited and acquired complement deficiency who developed invasive
meningococcal disease (IMD) in England over the last decade.
Methods: Public Health England conducts enhanced surveillance of IMD in England. We retrospectively identified
patients with complement deficiency who developed IMD in England during 2008–2017 and retrieved information
on their clinical presentation, vaccination status, medication history, recurrence of infection and outcomes, as well
as characteristics of the infecting meningococcal strain.
Results: A total of 16 patients with 20 IMD episodes were identified, including four with two episodes. Six patients
had inherited complement deficiencies, two had immune-mediated conditions associated with complement
deficiency (glomerulonephritis and vasculitis), and eight others were on Eculizumab therapy, five for paroxysmal
nocturnal haemoglobinuria and three for atypical haemolytic uraemic syndrome. Cultures were available for 7 of 11
episodes among those with inherited complement deficiencies/immune-mediated conditions and the predominant
capsular group was Y (7/11), followed by B (3/11) and non-groupable (1/11) strains. Among patients receiving
Eculizumab therapy, 3 of the 9 episodes were due to group B (3/9), three others were NG but genotypically group
B, and one case each of groups E, W and Y.
Conclusions: In England, complement deficiency is rare among IMD cases and includes inherited disorders of the
late complement pathway, immune-mediated disorders associated with low complement levels and patients on
Eculizumab therapy. IMD due to capsular group Y predominates in patient with inherited complement deficiency,
whilst those on Eculizumab therapy develop IMD due to more diverse capsular groups including non-encapsulated
strains.
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Background
Neisseria meningitidis (the meningococcus) remains a
leading cause of bacterial meningitis and septicaemia
worldwide, despite continued advances in the under-
standing of the pathogenesis of infection and develop-
ment of new vaccines against this devastating infection.
The meningococcus is commonly carried in the human
nasopharynx, especially in adolescents and young adults
[1, 2]. In recent years, genome-wide association studies
[3] have identified host factors which may contribute to
disease susceptibility; in particular, interaction between
the complement system and the meningococcus has
proven to be important in the pathogenesis of invasive
meningococcal disease (IMD). IMD usually affects
healthy individuals, in which a functional complement
system acts as a first-line innate immune defence against
invading pathogens [4]. Defects in components of the
alternative pathway (properdin and factor D) as well as
the terminal pathway (C5 to C9) underlie susceptibility
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: shamez.ladhani@phe.gov.uk
1Immunisation and Countermeasures Division, Public Health England, 61
Colindale Avenue, London NW9 5EQ, UK
2Paediatric Infectious Diseases Research Group & Vaccine Institute, Institute of
Infection & Immunity, St. Georges, University of London, London, UK
Full list of author information is available at the end of the article
Ladhani et al. BMC Infectious Diseases          (2019) 19:522 
https://doi.org/10.1186/s12879-019-4146-5
to IMD [5]. Individuals with primary immunodeficien-
cies such as the autosomal recessive terminal comple-
ment pathway deficiencies have a 7000–10,000 fold
higher risk of IMD compared to the general population
and more than half of these patients develop recurrent
episodes of IMD [6].
In addition to inherited deficiencies of the terminal
complement pathway, a number of medical conditions
and treatments can lead to acquired or secondary com-
plement deficiency. In particular, Eculizumab (Soliris®;
Alexion) is a humanised monoclonal antibody that is a
terminal complement pathway inhibitor used to treat
paroxysmal nocturnal haemoglobinuria (PNH) [7]
and atypical haemolytic uraemic syndrome (aHUS) [8],
and its use is extending to treat other immune-mediated
conditions [9–13]. Eculizumab binds with high affinity
to human complement C5 and blocks the generation of
C5a and C5b-9, which prevents the formation of mem-
brane attack complexes and activation of the pro-inflam-
matory pathway, thus protecting against end-organ
damage [7].
Characterising cases of IMD in individuals with com-
plement deficiencies is fundamental to understanding
disease risk in this highly vulnerable population and de-
veloping evidence-based guidance to both prevent and
rapidly treat this potentially fatal condition. Public
Health England (PHE) conducts enhanced national sur-
veillance of IMD in England and routinely follows-up all
cases confirmed by its national Meningococcal Reference
Unit (MRU). Here we describe age distribution, clinical
presentation, risk of recurrence, meningococcal typing
and outcome of IMD in individuals with inherited or ac-
quired complement deficiency diagnosed in England
over a ten-year period.
Methods
In England, National Health Service (NHS) hospital
laboratories routinely submit invasive meningococcal
isolates to the PHE MRU for confirmation, grouping
and additional characterisation [14]. The MRU also of-
fers a free national PCR-testing service for patients with
suspected IMD across England. IMD was defined as
Neisseria meningitidis identified by culture or PCR
from a sterile site. Confirmed cases are routinely
followed up through postal questionnaires sent to their
general practitioners for information on vaccination
status, underlying co-morbidities, clinical presentation
and outcomes of infection. For this study, IMD cases in
patients with inherited or acquired complement defi-
ciency diagnosed in England during 2008–2017 were
included. Culture and non-culture samples submitted
to the PHE MRU were characterised as reported
previously [14–16].
Results
A total of 16 complement-deficient patients with 20 epi-
sodes of IMD were identified during the surveillance
period (Table 1). For all 20 episodes, the diagnosis was
confirmed by blood culture, PCR-positive whole blood
EDTA or both. Of the four cases with two IMD episodes
each, the first episode occurred prior to the surveillance
period in two and, for the other two, both cases
occurred during the surveillance period. In three of the
four patients with repeat IMD episodes, the infections
were due to different capsular groups; interestingly, all
three involved one episode each of group B and group
W IMD. In the fourth patient, the two IMD episodes
occurred more than 2 years apart and were caused by a
NG(B) strain (i.e. non-groupable because of interruption
of ctrA gene but genotypically capsular group B) that
was confirmed by PCR only; the 2 NG(B) strains were
indistinguishable in terms of PorA (P1.7–1,1) and fHbp
(variant 2 peptide 23).
Six patients had inherited complement deficiencies, and
two others had immune-mediated conditions associated
with complement deficiency. The age range for those with
inherited complement deficiencies or immune-mediated
conditions was 4 to 42 years with a median age of 15 years.
The first case with an immune-mediated condition affect-
ing complement had hypocomplementaemic urticarial vas-
culitis (anti-C1q vasculitis) which was first diagnosed in
2010 when the patient developed infective endocarditis
needing mitral valve repair, ischaemic cerebral events,
lower limb amputation and endophthalmitis resulting in
complete loss of vision in one eye. This patient developed
IMD 3 years later whilst on immunosuppressive therapy
for the underlying condition. The second case with an
immune-mediated condition affecting complement devel-
oped IMD in 2012 and was diagnosed with membranopro-
liferative glomerulonephritis associated with persistently
low complement factors C3 and C4 four months later.
Eight other patients were on Eculizumab therapy, five
for paroxysmal nocturnal haemoglobinuria (PNH) and
three for atypical haemolytic uraemic syndrome (aHUS).
The age range of patients on Eculizumab therapy was 20
to 40 years with a median age of 22 years. Overall, cul-
tures were available for 7 of 11 episodes in patients with
inherited complement deficiencies or immune-mediated
conditions, and 6 of 9 episodes in patients receiving Ecu-
lizumab therapy despite national recommendations for
daily antibiotic chemoprophylaxis in this vulnerable
group. The rest of IMD episodes were confirmed by
PCR only.
The predominant capsular group for the inherited
complement deficiencies or immune-mediated condi-
tions was capsular group Y (7/11), followed by capsular
group B (3/11); one strain that was non-groupable by
PCR (i.e. ctrA positive but not positive for capsular
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groups A, B, C, W or Y), suggesting a truly non-
groupable strain or a rare capsular group. For those on
Eculizumab therapy, six of the nine isolates were due to
either capsular group B (n = 3) or non-groupable (inter-
ruption of ctrA gene) but genotypically capsular group B
(NG(B); n = 3). Three other episodes were due to capsu-
lar groups W, Y and E. Capsular group Y strains was
mainly associated with PorA P1.5–1,10–1. One isolate
was penicillin-resistant - a non-groupable strain that was
genotypically characterised as group B [17].
Four cases had recurrent IMD episodes, three who
were diagnosed with an inherited complement defi-
ciency after their second IMD episode, and one in a
renal patient on Eculizumab therapy. Case 2 with com-
plement C6 deficiency developed IMD due to capsular
group B at 15 years of age, followed by IMD due to cap-
sular group Y 9 years later. This case was on rescue anti-
biotics (i.e. self-treatment with a treatment course of
amoxycillin when unwell) at the time and only received
the MenACWY conjugate vaccine after the second epi-
sode of IMD. Case 3 with complement C8 deficiency
had two episodes of IMD at 20 and 42 years of age due
to capsular group Y and B, respectively; this patient was
prescribed prophylactic amoxycillin twice daily following
the second episode. Case 5 was diagnosed with comple-
ment C6 deficiency after the second IMD episode. This
case developed IMD due to capsular group B at 4 years
of age and then with capsular group Y at 16 years; the
patient had received the MenACWY conjugate vaccine
as part of the national UK adolescent programme 2
years prior to the second episode of IMD. Case 16 with
aHUS commenced Eculizumab therapy aged 20 years
and presented with IMD at 20 and 22 years of age after
been appropriately vaccinated with a single dose of
MenACWY conjugate vaccine and two doses of the
meningococcal group B vaccine, 4CMenB. This patient
was reported to be intermittently non-compliant with
antibiotics. Both IMD episodes were confirmed by PCR
only; the infecting strains were both PCR negative for
the ctrA gene, but genotypically confirmed as capsular
group B. Both strains had porA P1.7–1,1 and factor H
binding protein variant 2 allele 23 peptide 23. Neither of
these antigenic variants are predicted to be covered by
4CMenB.
Discussion
We identified 16 individuals with invasive meningococcal
disease who had confirmed primary or acquired comple-
ment deficiency in England over a decade. Most cases de-
veloped IMD during adolescence and early adulthood,
including four who developed recurrent IMD; three of the
four cases were diagnosed with an underlying primary com-
plement deficiency after the second IMD episode. In
addition to the primary complement deficiencies, we identi-
fied two groups with acquired complement deficiency,
those with immune disorders leading to secondary comple-
ment deficiency and iatrogenic cases in patients receiving
Eculizumab, a humanised monoclonal complement C5
inhibitor.
The complement system is an important component
of the innate immune defence against invading bacteria
including meningococci; complement activation on cell -
surfaces may be initiated through any of the three path-
ways - the classical, lectin, or alternative pathways. The
terminal complement pathway comprises five proteins
(C5-C9) that combine together to form a lethal pore-like
membrane attack complex (MAC), which disrupts the
bacterial cell membrane and forms transmembrane
channels, leading to bacterial lysis [4]. Complement defi-
ciencies represent approximately 1–6% of all primary
immunodeficiencies but this may go up to 10% of pri-
mary immunodeficiencies in certain communities [18].
The prevalence of inherited complement deficiency has
been calculated to be about 0.03% in the general Euro-
pean population [18], excluding mannose-binding lectin
(MBL) deficiency, which has been estimated to occur in
its homozygous form in about 5% of the population [19].
In our cohort, we observed an over-representation of
IMD due to capsular group Y in those with inherited
complement deficiencies (7/11, 64%) compared to those
receiving Eculizumab therapy (1/9, 11%); the risk of
group Y IMD in the latter group is similar to the rest of
the population - in England, IMD due to group Y was
responsible for 10.9% of all cases during 2011–15 [20].
In the UK, group Y is commonly carried in teenagers,
with nasopharyngeal carriage rates of 10.0%, 10.1% and
9.7% among 15–19 year olds during 1999, 2000 and
2001, respectively [21]. During 2010–11, carriage of
group Y meningococci among 18–24 year-olds in Eng-
land was 7% [22].
Another significant difference between the inherited
complement deficiencies and the patients on Eculizumab
therapy was that all but one strain (8/9 strains, including
six with group Y and two with group B) causing IMD in
patients with inherited complement deficiencies were
encapsulated, as were both the strains causing IMD in
patients with immune-mediated conditions associated
with complement deficiency (both group Y). In contrast,
four of the nine IMD episodes in patients on Eculizumab
therapy were either NG or group E; these strains are less
virulent and usually only associated with carriage.
Our findings support the recent French report of 56
cases with terminal complement pathway deficiency who
developed 61 episodes IMD between 1980 and 2015 [5].
They also found that patients with terminal complement
deficiency were more likely to develop IMD due to minor
or uncommon meningococcal serogroups, especially MenY
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which was responsible for 44% (27/61) of all cases, but also
W and NG strains, although no correlation was found
between specific terminal complement deficiencies and
capsular group or clonal complex. Notably, as in our study,
most isolates from patients with terminal complement
deficiency were groupable, indicating that they were able
to express capsule and could, therefore, be pathogenic [5].
A new and significant finding in our cohort was that
there were more patients with IMD who were on
Eculizumab treatment than those with primary terminal
complement deficiency, including six treated for PNH
and three for aHUS. An unwanted complication of
complement inhibition, however, is an increased risk of
infection with encapsulated bacteria, especially IMD.
Unfortunately, just like patients with primary terminal
complement deficiency, this group remains at increased
risk of IMD even after appropriate immunisation
because they are unable to mediate meningococcal lysis
by the membrane attack complex. This finding empha-
sises the importance of penicillin chemoprophylaxis to
prevent IMD and other serious bacterial infections in
high-risk patients. Whilst there are no published guide-
lines on the management of individuals with inherited
complement deficiencies or immune-mediated condi-
tions associated with hypocomplementaemia, antibiotic
chemoprophylaxis is routinely recommended for those
with asplenia and those receiving Eculizumab. We have,
however, recently reported a case of penicillin-resistant
MenB disease in a vaccinated young adult on penicillin
prophylaxis, highlighting the need to raise awareness of
IMD risk among patients and healthcare professionals,
as well as the need to seek early medical attention and
for early investigation and treatment in unwell patients
receiving Eculizumab, who usually present with non-
specific symptoms and signs of infection. Although none
of the patients in our cohort died of IMD, there have
been reports of fatalities due to NG strains in patients
receiving Eculizumab [23].
In addition to the known risk factors for IMD, we found
other rare conditions associated with complement defi-
ciencies, such as hypocomplementaemic urticarial vascu-
litis (anti-C1q vasculitis), which is associated with
glomerulonephritis [24] as well as some forms of membra-
noproliferative glomerulonephritis. Conditions associated
with acquired immune deficiencies include inadequate
complement production (e.g., severe liver dysfunction),
increased complement consumption (autoimmune disor-
ders, diseases associated with immune complex forma-
tion), or increased excretion of complement components
(e.g., protein-losing nephropathies) [4]. Around half the
patients with systemic lupus erythematosus (SLE) have
low C3 and C4 complement concentrations. C3 is the
most abundant complement protein and its cleavage and
the stable, covalent linkage of its fragments to target
surfaces is a critical outcome of complement activation.
Notably, some forms of glomerulonephritis, such as those
associated with C3 nephritic factor, have responded to
treatment with Eculizumab [25].
IMD in patients with complement deficiency is generally
associated with mild disease, possibly due to a less intense
inflammatory response in the absence of an intact comple-
ment pathway. Fatal cases have, however, been reported,
including IMD cases due to NG meningococci, which gen-
erally only attack vulnerable hosts [23]. In addition to
highly effective polysaccharide-conjugate vaccines against
group A, C, W and Y meningococcal disease (MenACWY),
there are two new broad-spectrum, protein-based menin-
gococcal vaccines licensed in Europe. These vaccines are
highly immunogenic in children and adults, and 4CMenB
has been shown to protect against IMD in infants and tod-
dlers in the field [26]. Patients with complement deficiency,
however, may still develop IMD despite high post-
immunisation antibody titres, again because of the lack of a
functional complement pathway; vaccine failure after both
MenACWY and 4CMenB have been reported in this vul-
nerable group, leading some specialists to recommend daily
penicillin prophylaxis.
Conclusions
Acquired and inherited deficiencies of the terminal com-
plement pathway are rare, even in patients with IMD.
Most cases of IMD in patients with inherited complement
deficiency occur during adolescence. Testing for comple-
ment deficiency after a single episode of IMD is not rou-
tinely recommended because the vast majority of patients
do not have any underlying co-morbidities. Healthcare
professionals should, however, consider the possibility of
inherited complement deficiency in any patient with re-
current IMD or in those who develop IMD due to unusual
capsular groups such as Y, E or NG meningococci, espe-
cially in previously healthy adolescents. The management
of such patients is challenging because of the limited pro-
tection offered by the current vaccines. In addition to vac-
cination, antibiotic chemoprophylaxis should be strongly
considered but rare cases of penicillin-resistant group
B meningococcal disease highlight the need to raise
awareness of IMD risk among patients and healthcare
professionals, including use of information cards to be
carried by patients and their care givers, as well as the
need to seek early medical attention and for early investi-
gation and treatment in unwell patients.
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